A Phase I, single-dose, multicenter, randomized, open-label, 3–parallel-arm study of risankizumab formulations (prefilled syringe and auto-injector for subcutaneous injection) in healthy adult subjects
Latest Information Update: 10 Feb 2021
At a glance
- Drugs Risankizumab (Primary)
- Indications Atopic dermatitis; Crohn's disease; Erythrodermic psoriasis; Hidradenitis suppurativa; Palmoplantar pustulosis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; Ulcerative colitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 10 Feb 2021 New trial record
- 03 Feb 2021 Results published in the Clinical Therapeutics